Association of anticholinergic drugs with hospitalization and mortality among older cardiovascular patients: A prospective study

Drugs and Aging

Volumn 28, Issue 2, 2011, Pages 131-138

  Uusvaara, Juho ^a   Pitkala, Kaisu H ^a,b   Kautiainen, Hannu ^c,d   Tilvis, Reijo S ^a   Strandberg, Timo E ^e  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c ORTON ORTHOPAEDIC HOSPITAL   (Finland)

^d JYVÄSKYLÄ CENTRAL HOSPITAL   (Finland)

^e UNIVERSITY OF OULU   (Finland)

Author keywords

Cardiovascular disorders; Cholinergic receptor antagonists, therapeutic use; Drug utilisation; Elderly; Hospitalisation; Mortality

Indexed keywords

ALPRAZOLAM; AMITRIPTYLINE; CAPTOPRIL; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLIDINIUM BROMIDE; CODEINE; CORTISONE ACETATE PLUS NEOMYCIN; DIAZEPAM; DIGOXIN; DIPYRIDAMOLE; DISOPYRAMIDE; DOXEPIN; EMEPRONIUM BROMIDE; FUROSEMIDE; HYDROXYZINE; IPRATROPIUM BROMIDE; ISOSORBIDE DINITRATE; ISOSORBIDE MONONITRATE; LEVOMEPROMAZINE; METOCLOPRAMIDE; NIFEDIPINE; ORPHENADRINE; OXYBUTYNIN; PERICIAZINE; PROCHLORPERAZINE; QUINIDINE; RANITIDINE; THEOPHYLLINE; TOLTERODINE; UNINDEXED DRUG;

ADULT; AGE DISTRIBUTION; ARTICLE; CARDIOVASCULAR DISEASE; CHARLSON COMORBIDITY INDEX; COGNITION; COMORBIDITY; CONTROLLED STUDY; DRUG USE; FEMALE; FINLAND; FOLLOW UP; HOSPITAL CARE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; MORTALITY; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCORING SYSTEM; SECONDARY PREVENTION; SEX DIFFERENCE;

AGE FACTORS; AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; CHOLINERGIC ANTAGONISTS; COGNITION DISORDERS; COHORT STUDIES; FEMALE; FINLAND; HOSPITALIZATION; HUMANS; INAPPROPRIATE PRESCRIBING; MALE; MULTIVARIATE ANALYSIS; PROGNOSIS; PROSPECTIVE STUDIES; RISK ASSESSMENT;

EID: 79551554509     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.2165/11585060-000000000-00000     Document Type: Article

References (46)

1. Ancelin M, Artero S, Portet F, et al. Non-degenerative mild cognitive impairment in elderly people and of anticholinergic drugs: longitudinal cohort study. BMJ 2006; 332: 455-9
2. Hajjar E, Cafiero A, Hanlon J. Polypharmacy in elderly patients. Am J Geriatr Pharmacother 2007; 5: 345-51
3. Beers MH, Ouslander JG, Rollinger I, et al. Explicit criteria for determining potentially inappropriate medication use in nursing home residents. Arch Intern Med 1991; 151: 1825-32
4. Beers MH. Explicit criteria for determining potentially inappropriate medication use by the elderly: an update. Arch Intern Med 1997; 157 (14): 1531-6
5. Gurwitz J, Field T, Harrold L, et al. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA 2003; 289: 1107-16
6. Roth M, Weinberger M, Campbell W. Measuring the quality of medication use in older adults. J Am Geriatr Soc 2009; 57: 1096-102
7. Han L, Agostini JV, Allore HG. Cumulative anticholinergic exposure is associated with poor memory and executive function in older men. J Am Geriatr Soc 2008; 56: 2203-10
8. Lechevallier-Michel N, Molimard M, Dartigues JF, et al. Drugs with anticholinergic properties and cognitive performance in the elderly: results from the PAQUID study. Br J Clin Pharmacol 2004; 59: 143-51
9. Low LF, Anstey KJ, Sachdev P. Use of medications with anticholinergic properties and cognitive function in a young-old community sample. Int J Geriatr Psychiatry 2009; 24: 578-84
10. Uusvaara J, Pitkala KH, Tienari PJ, et al. Association between anticholinergic drugs and apolipoprotein E e4 allele and poorer cognitive function in older cardiovascular patients: a cross-sectional study. J Am Geriatr Soc 2009; 57: 427-31
11. Carrière I, Fourrier-Reglat A, Dartigues J-F, et al. Drugs with anticholinergic properties, cognitive decline, and dementia in an elderly general population. Arch Intern Med 2009; 169: 1317-24
12. Flacker JM, Cummins V, Mach JR, et al. The association of serum anticholinergic activity with delirium in elderly medical patients. Am J Geriatr Psychiatry 1998; 6: 31-41
13. Han L, McCusker J, Cole M, et al. Use of medications with anticholinergic effect predicts clinical severity of delirium symptoms in older medical inpatients. Arch Intern Med 2001; 161: 1099-105
14. Rudolph JL, Salow MJ, Angelini MC, et al. The anticholinergic risk scale and anticholinergic adverse effects in older persons. Arch Intern Med 2008; 168: 508-13
15. Chrischilles E, VanGilder R, Wright K, et al. Inappropriate medication use as a risk factor for self-reported adverse drug effects in older adults. JAmGeriatr Soc 2009; 57: 1000-6
16. Landi F, Russo A, Liperoti R, et al. Anticholinergic drugs and physical function among frail elderly population. Clin Pharmacol Ther 2007; 81: 235-41
17. Panula J, Puustinen J, Jaatinen P, et al. Effects of potent anticholinergics, sedatives and antipsychotics on postoperative mortality in elderly patients with hip fracture: a retrospective, population-based study. Drugs Aging 2009; 26: 963-71
18. Strandberg TE, Pitkala KH, Tilvis RS. Multifactorial cardiovascular prevention in patients aged 75 and older: randomized controlled trial: drugs and evidence based treatment in the elderly (DEBATE) Study. Am Heart J 2001; 142: 945-51
19. Strandberg TE, Pitkala KH, Berglind S, et al. Possibilities of multifactorial cardiovascular disease prevention in patients aged 75 and older: a randomized, controlled trial - Drugs and Evidence-based treatment in the Elderly (DEBATE) Study. Eur Heart J 2003; 24: 1216-22
20. Wood D, De Backer G, Faergeman O, et al. Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. Eur Heart J 1998; 19: 1434-503
21. Strandberg TE, Pitkala KH, Berglind S, et al. Multifactorial intervention to prevent recurrent cardiovascular events in patients 75 years or older: the Drugs and Evidence-Based Medicine in the Elderly (DEBATE) study: a randomized, controlled trial. Am Heart J 2006; 152: 585-92
22. Folstein MF, Folstein SE,McHugh PR. 'Mini-mental state': a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-98
23. Wenham PR, Price WH, Blandell G. Apolipoprotein E genotyping by one-stage PCR. Lancet 1991; 337 (8750): 1158-9
24. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J ChronDis 1987; 40 (5): 373-83
25. Mintzer J, Burns A. Anticholinergic side-effects of drugs in elderly people. J R Soc Med 2000; 93: 457-62
26. Chutka D, Takahashi P, Hoel R. Inappropriate medications for elderly patients. Mayo Clin Proc 2004; 79: 122-39
27. Herbison P, Hay-Smith J, Ellis G, et al. Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review. BMJ 2003; 326: 841-4
28. Mulsant B, Pollock B, Kirshner M, et al. Serum anticholinergic activity in a community-based sample of older adults. Arch Gen Psychiatry 2003; 60: 198-203
29. Liu H, Farley J. Effects of first and second generation antihistamines on muscarinic induced mucus gland cell ion transport. BMC Pharmacol 2005; 5: 8
30. DeMaagd G, Geibig J. An overview of overactive bladder and its pharmacological management with a focus on anticholinergic drugs. P&T 2006; 31: 462-71
31. Seale P. Anticholinergic bronchodilatators. Aust Prescr 2003; 26: 33-5
32. Tandon R, Taylor S, Quardo J, et al. The cholinergic system in schizophrenia reconsidered: anticholinergic modulation of sleep and symptom profiles. Neuropsychopharmacology 1999; 21: 189-202
33. Shiraishi M, Minami K, Uezono Y, et al. Inhibition by tramadol of muscarinic receptor-induced responses in cultured adrenal medullary cells and in Xenopus laevis oocytes. J Pharmacol Exp Ther 2001; 299 (1): 255-60
34. Tune L, Carr S,Hoag E, et al. Anticholinergic effects of drugs commonly prescribed for the elderly: potential means for assessing risk of delirium. Am J Psychiatry 1992; 149: 1393-4
35. Saito M, Shibata O, Yamaguchi M, et al. Metoclopramide causes airway smooth muscle relaxation through inhibition of muscarinic M3 receptor in the rat trachea. Anesth Analg 2004; 98: 325-9
36. Isah A, Rawlins M, Bateman D. The pharmacokinetics and effects of prochlorperazine in elderly female volunteers. Oxf J 1991; 21: 27-31
37. Kay G, Abou-Donia M, Messer W, et al. Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients. J AmGeriatr Soc 2005; 53 (12): 2195-201
38. Cechin EM, Quevedo J, Barichello T, et al. Dose-related effects of propericiazine in rats. Braz JMed Biol Res 2003; 36: 227-31
39. World Health Organization. International statistical classification of diseases and related health problems. 10th ed. Geneva: World Health Organization, 1992
40. Pitkala KH, Laurila JV, Strandberg TE, et al. Prognostic significance of delirium in frail older people. Dement Geriatr Cogn Disord 2005; 19: 158-63
41. Salpeter SR, Buckley NS, Salpeter EE. Meta-analysis: anticholinergics, but not b-agonists, reduce severe exacerbations and respiratory mortality in COPD. J Gen Intern Med 2006; 21: 1011-9
42. Kelman HR, Thomas C, Kennedy GJ, et al. Cognitive impairment and mortality in older community residents. Am J Public Health 1994; 84: 1255-60
43. Bassuk SS, Wypij D, Berkmann LF. Cognitive impairment and mortality in the community-dwelling elderly. Am J Epidemiol 2000; 151: 676-88
44. Hanlon JT, Fillenbaum GG, Kuchibhatla M, et al. Impact of inappropriate drug use on mortality and functional status in representative community dwelling elders. Med Care 2002; 40: 166-76
45. Corsonello A, Pedone C, Lattanzio F, et al. Potentially inappropriate medications and functional decline in elderly hospitalized patients. J Am Geriatr Soc 2009; 57: 1007-14
46. Jano E, Aparasu R. Healthcare outcomes associated with Beers' criteria: a systematic review. Ann Pharmacother 2007; 41: 438-48